ОСОБЕННОСТИ КЛИНИЧЕСКИХ ПРОЯВЛЕНИЙ ГИПЕРТРОФИЧЕСКОЙ КАРДИОМИОПАТИИ У ПАЦИЕНТОВ С РАЗЛИЧНЫМИ МУТАЦИЯМИ В ГЕНАХ САРКОМЕРОВ

Цель. Оценка клинических проявлений заболевания у пациентов с ГКМП, имеющих мутации в генах белков саркомера кардиомиоцитов.

Материал и методы. У 11 пациентов с гипертрофической кардиомиопатией (ГКМП) проведен анализ клиническо-инструментальных данных и поиск мутаций в кодирующих последовательностях генов ACTC1, MYBPC3, MYH7, MYL2, MYL3, TNNI3, TNNT2 и TPM1 методом секвенирования следующего поколения (next-generation sequencing (NGS).

Результаты. Дано описание клинической картины ГКМП и анализ развития осложнений за период наблюдения у пациентов с мутациями в генах, кодирующих белки саркомера: Arg403Trp, Lys847del и Arg1712Trp (ген MYH7); Gln1233Term, Trp1214Arg, Arg502Gln, Arg326Gln и Ser236Gly (ген MYBPC3); Arg58Gln в гене MYL2.

Заключение. Обнаруженные мутации в генах саркомеров у пациентов с ГКМП ассоциированы с ранней клинической манифестацией заболевания, с отягощенным семейным анамнезом и развитием осложнений в процессе наблюдения.

1. Maron BJ, McKenna WJ, Danielson GK, et al. A repot of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. JASS 2003; 42: 1687-13.

2. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years clinical perspectives. J Am Coll Cardiol. 2012; 60: 705-15.

3. Keren A, Syrris P, McKenna WJ. Hypertrophic Cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 2008; 5(3): 158-68.

4. Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-analysis of genotypephenotype assotiation in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart 2013; 99: 1800-11.

5. Kelly M, Semsarian C. Multiple mutations in genetic cardiovascular disease: a marker of disease severity. Circ Cardiovasc Genet 2009; 2: 182-90.

6. Olivotto I, Girolami F, Ackermab MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008; 83(6): 630-80.

7. Gersh BJ, Maron BJ, Bonow RO, et al. Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation /American Heart Association Task Force on Practice Guidelines. J of the American College of Cardiology. 2011; 11: 1-49.

8. Danecek P, Auton A, Abecasis G, et al. The variant call format and VCFtools. Bioinformatics 2011; 27(15): 2156-8.

9. Yamashita H, Tyska M, Warshaw D, et al. Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic

10. cardiomyopathy. J Biol Chem 2000; 275(36): 28045-52.

11. Devlin A.M, Östman-Smith I. Diagnosis of hypertrophic cardiomyopathy and screening for the phenotype suggestive of gene carriage in familial disease: a simple echocardiographic procedure. J Med Screen 2000; 7: 82-90.

12. Al-Mahdawi S, Chamberlain S, Chojnowska L, et al. The electrocardiogram is a more sensitive indicator than echocardiography of hypertrophic cardiomyopathy in families with a mutation in the MYH7 gene. Br Heart J 1994; 72(2): 105-11.

13. Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 2004; 44(11): 2192-201.

14. Wang H, Song L, Zou YB, et al. A novel hot-spot mutation S236G in the cardiac myosin binding protein C gene in Chinese patient with hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 2009; 37(12): 1078-80.

15. Jääskeläinen P ., Kuusisto J., Miettinen R . et al. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland. J Mol Med (Berl) 2002; 80(7): 412-22.

16. Christiaans I, Birnie E, van Langen IM, et al. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. Eur Heart J 2010; 31(7): 842-8.

17. Bashyam MD, Purushotham G, Chaudhary AK, et al. A low prevalence of MYH7/MYBPC3 mutations among familial hypertrophic cardiomyopathy patients in India. Mol Cell Biochem 2012; 360(1-2): 373-82.

18. Van Driest SL, Jaeger MA, Ommen SR, et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44(3): 602-10.

19. Rodríguez-García MI, Monserrat L, Ortiz M, et al. Screening mutations in myosin binding protein C3 gene in a cohort of patients with Hypertrophic Cardiomyopathy. BMC Medical Genetics 2010, 11: 67.

20. Hougs L, Havndrup O, Bundgaard H, et al. One third of Danish hypertrophic cardiomyopathy patients with MYH7 mutations have mutations [corrected] in MYH7 rod region. Eur J Hum Genet 2005; 13(2): 161-5.

21. Erdmann J, Raible J, Maki-Abadi J, et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 2001; 38(2): 322-30.

22. Ehlermann P, Weichenhan D, Zehelein J, et al. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med Genet 2008; 9: 95.

23. Flavigny J, Richard P, Isnard R, et al. Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J Mol Med 1998; 76: 208-14.

24. Kabaeva ZT, Perrot A, Wolter B, et al. Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy. Eur J Hum Genet 2002; 10(11): 741-8.